CDSCO Approves India's First Tumour-Agnostic ADC Therapy
In News
What Happened
Why It Matters
Background
History & Context
What Changed
- ▶
BEFORE: Trastuzumab Deruxtecan was approved strictly for specific cancer types like HER2-positive breast and gastric cancers. NOW: It holds a tumour-agnostic approval, meaning it can be used for any HER2-positive solid tumor.
- ▶
BEFORE: Cancer treatment protocols were heavily dictated by the primary organ site where the tumor originated. NOW: Treatment can be guided by the tumor's molecular signature (HER2 expression), regardless of its anatomical location.
- ▶
BEFORE: Patients with rare HER2-mutated solid tumors had very limited targeted therapy options after failing standard treatments. NOW: These patients have access to a proven, highly targeted ADC therapy.
Prelims Angle
NCERT Connection
Practice Questions
Q1
With Reference ToWith reference to Tumour-Agnostic therapies and Antibody-Drug Conjugates (ADCs), consider the following statements: 1. Tumour-agnostic therapies treat cancer based on the organ of origin rather than the tumor's molecular characteristics. 2. Trastuzumab Deruxtecan utilizes monoclonal antibodies to deliver cytotoxic drugs directly to HER2-positive cancer cells. Which of the statements given above is/are correct?